ACAD vs MKC · P/E 15, rev $957.8M vs P/E 8.4, $13.56B cap
ACADIA Pharmaceuticals Inc (ACAD) versus McCormick & Company Incorporated (MKC) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
McCormick & Company Incorporated (MKC) is a packaged foods company listed on US.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
MKC does not have a complete income-statement cache yet.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
Not investment advice. Open the ACAD and MKC stock pages for the full models.
Not investment advice.